Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1994 1
1995 2
1997 4
1998 3
1999 1
2000 1
2003 1
2006 2
2007 5
2008 2
2009 5
2010 2
2011 4
2012 3
2013 4
2014 2
2015 6
2016 7
2017 6
2018 6
2019 2
2020 3
2021 3
2022 7
2023 4
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Topical bromfenac in VEGF-driven maculopathies: topical review and meta-analysis.
Kulikov AN, Vasiliev AS, Kalinicheva YA, Maltsev DS. Kulikov AN, et al. BMC Ophthalmol. 2024 Aug 23;24(1):369. doi: 10.1186/s12886-024-03650-z. BMC Ophthalmol. 2024. PMID: 39180057 Free PMC article. Review.
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven maculopathies. ...At the same time, eyes receiving bromfenac as an adjunct to anti-VEGF therapy demonstrated non-inferior outcomes in cen …
In this review, we focused on the advantages of topical bromfenac as an adjunct to intravitreal anti-VEGF therapy in VEGF-driven macu …
Topical bromfenac as adjunctive treatment with intravitreal ranibizumab for diabetic macular edema.
Gabr AF, Kamel MF, Elbarawy AA. Gabr AF, et al. Int Ophthalmol. 2023 Sep;43(9):3219-3226. doi: 10.1007/s10792-023-02722-1. Epub 2023 Apr 21. Int Ophthalmol. 2023. PMID: 37083870 Free PMC article. Clinical Trial.
The efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, central and average thickness and the need for re-injection. ...No side effects was encountered with the use of topical bromfenac. CONCLUSI …
The efficacy of topical bromfenac was evaluated by comparing both groups through follow-up period as regards to visual acuity, centra …
Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients.
Matsumura T, Iwasaki K, Arimura S, Takeda R, Takamura Y, Inatani M. Matsumura T, et al. Sci Rep. 2021 Mar 16;11(1):6018. doi: 10.1038/s41598-021-85495-w. Sci Rep. 2021. PMID: 33727659 Free PMC article. Clinical Trial.
Platelet-derived growth factor-AA levels significantly decreased in both drug groups, but they were significantly higher in the fluorometholone group than in the bromfenac group (P = 0.034). Bromfenac also significantly decreased vascular endothelial growth factor l …
Platelet-derived growth factor-AA levels significantly decreased in both drug groups, but they were significantly higher in the fluoromethol …
Bromfenac sodium, acetaminophen/oxycodone, ibuprofen, and placebo for relief of postoperative pain.
Johnson GH, Van Wagoner JD, Brown J, Cooper SA. Johnson GH, et al. Clin Ther. 1997 May-Jun;19(3):507-19. doi: 10.1016/s0149-2918(97)80135-x. Clin Ther. 1997. PMID: 9220215 Clinical Trial.
In the multiple-dose phase, 204 patients received bromfenac, acetaminophen/oxycodone, or ibuprofen for up to 5 days. In the single-dose phase, both bromfenac doses produced peak analgesic responses equivalent to acetaminophen/oxycodone, but the responses to bromf
In the multiple-dose phase, 204 patients received bromfenac, acetaminophen/oxycodone, or ibuprofen for up to 5 days. In the single-do …
Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
Walters TR, Goldberg DF, Peace JH, Gow JA; Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Walters TR, et al. Ophthalmology. 2014 Jan;121(1):25-33. doi: 10.1016/j.ophtha.2013.07.006. Epub 2013 Sep 8. Ophthalmology. 2014. PMID: 24021896 Clinical Trial.

A statistically significantly higher proportion of subjects in the bromfenac 0.07% group were pain free at all study visits compared with those in the placebo group (P < 0.0001). Fewer subjects in the bromfenac group (3.2%) discontinued investigational product ea

A statistically significantly higher proportion of subjects in the bromfenac 0.07% group were pain free at all study visits compared …
Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Donnenfeld ED, et al. Ophthalmology. 2007 Sep;114(9):1653-62. doi: 10.1016/j.ophtha.2006.12.029. Epub 2007 Apr 19. Ophthalmology. 2007. PMID: 17445902 Clinical Trial.
The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P<0.0001). Numbers of most ocular adverse events were lower for the bromfenac group than for the placebo group. ...There were no serious ocular adverse events, and fewer …
The median time to resolution of ocular pain was 2 days (bromfenac) versus 5 days (placebo) (P<0.0001). Numbers of most ocular adv …
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
Goldkind L, Laine L. Goldkind L, et al. Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):213-20. doi: 10.1002/pds.1207. Pharmacoepidemiol Drug Saf. 2006. PMID: 16456879
There were very limited published data on benoxaprofen and none on ibufenac or bromfenac. The publicly accessible archives of the FDA provided information on bromfenac. ...Following approval, rates of acute liver failure for bromfenac were estimated to be in …
There were very limited published data on benoxaprofen and none on ibufenac or bromfenac. The publicly accessible archives of the FDA …
Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F, Sawa M, Tsujikawa M, Nishida K. Gomi F, et al. Retina. 2012 Oct;32(9):1804-10. doi: 10.1097/IAE.0b013e31825be87f. Retina. 2012. PMID: 22718152 Clinical Trial.
The changes in visual acuity did not differ significantly (P = 0.3141) although the central retinal thickness was tended to decrease more in bromfenac group (P = 0.0604). Multivariate analysis showed that topical bromfenac is significantly associated with fewer rani …
The changes in visual acuity did not differ significantly (P = 0.3141) although the central retinal thickness was tended to decrease more in …
EFFECT OF BROMFENAC ON PAIN RELATED TO INTRAVITREAL INJECTIONS: A Randomized Crossover Study.
Georgakopoulos CD, Tsapardoni F, Makri OE. Georgakopoulos CD, et al. Retina. 2017 Feb;37(2):388-395. doi: 10.1097/IAE.0000000000001137. Retina. 2017. PMID: 27442130 Clinical Trial.
PURPOSE: To evaluate the analgesic effect of bromfenac, a topically administered nonsteroidal antiinflammatory agent, in patients undergoing intravitreal injections (IVIs) of anti-vascular endothelial growth factor agents. ...CONCLUSION: Topical instillation of bromfena
PURPOSE: To evaluate the analgesic effect of bromfenac, a topically administered nonsteroidal antiinflammatory agent, in patients und …
Topical 0.1% Nepafenac versus 0.09% Bromfenac Eye Drops for Inflammation after Laser Peripheral Iridotomy: A Randomized Controlled Trial.
Shankar LG, Odayappan A, Shukla AG, Ramaswamy VC, Rengaraj V, Srinivasan K. Shankar LG, et al. Ophthalmol Glaucoma. 2022 Sep-Oct;5(5):516-524. doi: 10.1016/j.ogla.2022.02.009. Epub 2022 Feb 20. Ophthalmol Glaucoma. 2022. PMID: 35196591 Clinical Trial.
Post-LPI burning, smarting, and stinging was more common in the bromfenac group (P = 0.01), which also had a higher comfort score on the Likert scale (P = 0.004). ...CONCLUSIONS: Topical 0.09% bromfenac is noninferior to 0.1% nepafenac in controlling inflammation af …
Post-LPI burning, smarting, and stinging was more common in the bromfenac group (P = 0.01), which also had a higher comfort score on …
85 results